申请人:Warner-Lambert Company
公开号:US03957772A1
公开(公告)日:1976-05-18
A novel process for preparing 4-hydroxy-3-(5-methyl-3-isoxazolylcarbamoyl)-2-methyl-2H-1,2-benzothiazine 1,1-dioxide (I), starting with 3-amino-5-methylisoxazole (II) is disclosed. Compound I exhibits anti-inflammatory properties and is useful for treating inflammation. In the process of the invention an intermediate obtained, 2,3-dihydro-N-(5-methyl-3-isoxazolyl)-3-oxo-1,2-benzisothiazole-2-acetamid e 1,1-dioxide (IV) undergoes rearrangement to provide 1-[5-(4-hydroxy-2H-1,2-benzothiazin-3-yl)-1,2,4-oxadiazol-3-yl]methyl}eth anone S,S-dioxide (V), which is methylated, according to conventional procedures. The methylated intermediate VI, upon further treatment, undergoes a second rearrangement to obtain the desired anti-inflammatory compound I.
揭示了一种用于制备4-羟基-3-(5-甲基-3-异噁唑基甲酰基)-2-甲基-2H-1,2-苯并噻嗪-1,1-二氧化物(I)的新工艺,以3-氨基-5-甲基异噁唑(II)为起始物。化合物I具有抗炎性能,并可用于治疗炎症。在该发明的过程中,获得一个中间体,2,3-二氢-N-(5-甲基-3-异噁唑基)-3-氧代-1,2-苯并噻唑-2-乙酰胺-1,1-二氧化物(IV)经过重排,得到1-[5-(4-羟基-2H-1,2-苯并噻嗪-3-基)-1,2,4-噁唑-3-基]甲基}乙酮S,S-二氧化物(V),然后按照常规程序对其进行甲基化。甲基化的中间体VI,在进一步处理后,经历第二次重排得到所需的抗炎化合物I。